Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Ligands: Novel Pharmacological Agents in the Treatment of Ischemia Reperfusion Injury

Title: Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Ligands: Novel Pharmacological Agents in the Treatment of Ischemia Reperfusion Injury

Volume: 8 Issue: 6

Author(s): Costas Giaginis, Gerasimos Tsourouflis and Stamatios Theocharis

Affiliation:

Keywords: Ischemia Reperfusion Injury, Peroxisome proliferator-activated receptor-γ (PPAR-γ), insulin sensitizers, human metabolic disorders, inflammatory, growth hormone protein-1 (GHP-1)

Abstract: Peroxisome proliferator-activated receptor-γ (PPAR-γ) ligands constitute important insulin sensitizers that have already been used for the treatment of human metabolic disorders, exerting also pleiotropic effects on inflammatory related diseases and cancer. Ischemia-reperfusion injury that is mainly associated with organ transplantation constitutes a serious complication with a great relevance in clinical practice. Accumulating experimental data have recently revealed that natural and synthetic PPAR-γ ligands exert beneficial effects against ischemia-reperfusion injury. The present review summarizes the available information on the role of PPAR-γ ligands in ischemia-reperfusion injury amongst the different organ systems. Taking into consideration the data so far, PPAR-γ ligands seem to represent potential therapeutic agents in the aim to reduce or even prevent injury associated with ischemia-reperfusion.

Cite this article as:

Giaginis Costas, Tsourouflis Gerasimos and Theocharis Stamatios, Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Ligands: Novel Pharmacological Agents in the Treatment of Ischemia Reperfusion Injury, Current Molecular Medicine 2008; 8 (6) . https://dx.doi.org/10.2174/156652408785748022